Literature DB >> 8980158

Effects of four years' treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults.

K A Al-Shoumer1, B Page, E Thomas, M Murphy, S A Beshyah, D G Johnston.   

Abstract

Short-term trials of growth hormone (GH) substitution in hypopituitary adults have shown beneficial effects on body composition. To evaluate the long-term effects on body composition, we followed thirteen GH-deficient adults (GH < 6 mU/l following standard provocative tests) for 4 years of GH replacement. At yearly intervals, serum insulin-like growth factor I (IGF-I), body weight, body mass index (BMI), waist, waist-to-hip circumference ratio (WHR) and resting systolic (SBP) and diastolic blood pressure (DBP) were determined, and body composition was assessed using three independent methods: total body potassium (TBK), bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA). Compared to baseline, IGF-I levels increased significantly at 1 (p = 0.0001), 2 (p = 0.0004), 3 (p = 0.006) and 4 years (p = 0.002). Body weight and BMI changed minimally at 1, 2 and 3 years and increased significantly only at the fourth year (p = 0.012 and p = 0.0009, respectively) of GH therapy. Waist and WHR decreased significantly at 1, 2 and 4 years (waist: p = 0.0009, p = 0.0004, p = 0.049; WHR: p = 0.0025, p = 0.012, p = 0.047, respectively). Neither resting SBP nor DBP changed significantly. Fat-free mass (FFM) derived from TBK and BIA increased significantly at 1 (p = 0.004; p = 0.004), 2 (p = 0.003; p = 0.05), 3 (p = 0.005; p = 0.04) and 4 years (p = 0.02; p = 0.002). Using DXA, the increase in FFM was significant at 1 (p = 0.007) and 2 years (p = 0.008) but not at 3 and 4 years. Percentage body fat measured by TBK, BIA and DXA decreased significantly at 1 (p = 0.008; p = 0.003; p = 0.03), 2 (p = 0.018; p = 0.06; p = 0.049) and 4 years (p = 0.03; p = 0.002; p = 0.04). A rise in total body water, calculated from BIA, was observed at 1 year (p = 0.004) and was maintained throughout the treatment period. These data demonstrate that 4 years of GH treatment in hypopituitary adults is associated with sustained improvement in body composition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8980158     DOI: 10.1530/eje.0.1350559

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

1.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

2.  Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement.

Authors:  Luciana Diniz Carneiro Spina; Débora Vieira Soares; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Flávia Lúcia Conceição; Mário Vaisman
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 3.  Medical management of hypopituitarism in patients with pituitary adenomas.

Authors:  Baha M Arafah
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

Review 4.  Diagnosis and treatment of growth hormone deficiency in adults.

Authors:  Atil Y Kargi; George R Merriam
Journal:  Nat Rev Endocrinol       Date:  2013-04-30       Impact factor: 43.330

Review 5.  Pituitary disorders. Drug treatment options.

Authors:  J J Orrego; A L Barkan
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 6.  [Growth hormone therapy in adults. Attempt to assess a decade of use].

Authors:  M Faust; C J Strasburger
Journal:  Internist (Berl)       Date:  2008-05       Impact factor: 0.743

Review 7.  The Heart of the Matter: Cardiac Manifestations of Endocrine Disease.

Authors:  Aditya John Binu; Kripa Elizabeth Cherian; Nitin Kapoor; Sujith Thomas Chacko; Oommen George; Thomas Vizhalil Paul
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec

8.  Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement.

Authors:  Mary L Reed; George R Merriam; Atil Y Kargi
Journal:  Front Endocrinol (Lausanne)       Date:  2013-06-04       Impact factor: 5.555

Review 9.  Brown adipose tissue: endocrine determinants of function and therapeutic manipulation as a novel treatment strategy for obesity.

Authors:  Narendra L Reddy; Bee K Tan; Thomas M Barber; Harpal S Randeva
Journal:  BMC Obes       Date:  2014-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.